Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darleukin - Philogen

Drug Profile

Darleukin - Philogen

Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2; L19-IL2 fusion protein

Latest Information Update: 28 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Philogen
  • Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Immunostimulants; Interleukin-2 receptor agonists; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma
  • No development reported Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Discontinued Atherosclerosis; Head and neck cancer; Pancreatic cancer

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in Netherlands (IV, Infusion)
  • 22 Oct 2018 Discontinued - Phase-I for Head and neck cancer (Combination therapy) (Intralesional)
  • 22 Oct 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top